Staging and treatment of advanced esophageal cancer

Current Opinion in Gastroenterology

Volumn 21, Issue 4, 2005, Pages 472-477

  Von Rahden, Burkhard H A ^a   Stein, Hubert J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Multimodal; Neoadjuvant; Positron emission tomography with fluoro desoxyglucose; Response prediction

Indexed keywords

FLUORODEOXYGLUCOSE;

ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPY; ESOPHAGUS CANCER; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; ULTRASOUND;

COMBINED MODALITY THERAPY; ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 21844456666     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Stein HJ, Siewert JR. Improved prognosis of resected esophageal cancer. World J Surg 2004; 28:520-525.
2. Law S, Wong KH, Kwok KF, et al. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 2004; 240:791-800. This analysis of a surgical series from a major center for esophageal surgery in Hong Kong focusses on predictive factors for pulmonary complications.
3. Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004; 78:1177-1183. This is an analysis of a surgical series of esophageal cancer resections from a major center in France. Differential analysis of subsequent periods clearly revealed improvement of the results by time.
4. Stein HJ, Feith M, Siewert, JR. Approach to early Barrett's cancer. World J Surg 2003; 27:1040-1046.
5. Siewert JR, Stein HJ, Feith M. Surgical approach to invasive adenocarcinoma of the distal esophagus (Barrett's cancer). World J Surg 2003; 27:1058-1061.
6. Stein HJ, Von Rahden BH, Siewert JR. Survival after oesophagectomy for cancer of the oesophagus. Langenbecks Arch Surg 2004. [Epub ahead of print, Jul 14].
7. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004; 91:540-551.
8. Siewert JR, von Rahden BHA. Multimodal Treatment in Gastrointestinal Tract Tumors: Consequences for Surgery. World J Surg 2005. [In print].
9. Heeren PA, van Westreenen HL, Geersing GJ, et al. Influence of tumor characteristics on the accuracy of endoscopic ultrasonography in staging cancer of the esophagus and esophagogastric junction. Endoscopy 2004; 36:966-971.
10. Marsman WA, van Wissen M, Bergman JJ, et al. Outcome of patients with esophageal carcinoma and suspicious celiac lymph nodes as determined by endoscopic ultrasonography. Endoscopy 2004; 36:961-965.
11. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22:3805-3812. This evaluation and meta-analysis supports the use of FDG-PET as a staging method in esophageal cancer.
12. Kato H, Miyazaki T, Nakajima M, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005; 103:148-156.
13. Kneist W, Schreckenberger M, Bartenstein P, et al. Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma. Arch Surg 2004; 139:1043-1049.
14. van Westreenen HL, Heeren PA, van Dullemen HM, et al. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg 2005; 9:54-61.
15. Larson SM, Schoder H, Yeung H. Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer. Cancer J 2004; 10:243-250. The combined PET/CT is a promising tool, allowing fusion of functional information on glucose metabolism by FDG-PET with morphological information by CT.
16. von Rahden BHA, Stein HJ. Therapy of Advanced Esophageal Malignancy. Curr Opin Gastroenterol 2004; 20:391-396.
17. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53:925-930. Further meta-analysis of six randomized controlled trials clearly indicated a survival benefit at 3 years for patients undergoing neoadjuvant RCTx. The study indicates that the beneficial role of subsequent surgery is limited to the responders.
18. Brücher BL, Stein HJ, Zimmermann F, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 2004; 30:963-971.
19. Brown WA, Thomas J, Gotley D, et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 2004; 91:199-204.
20. Kalha I, Kaw M, Fukami N, et al. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer 2004; 101:940-947. This retrospective analysis clearly indicates that EUS is not appropriate for restaging after chemoradiation.
21. Agarwal B, Swisher S, Ajani J, et al. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol 2004; 99:1258-1266. This study indicates that information about residual lymphadenopathy given by EUS may be useful during response evaluation after neoadjuvant treatment. Nevertheless, the proposed use of FNAC for identification of residual tumor tissue appears dispensable.
22. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004; 101:1776-1785. The authors review the usefulness of FDG-PET for response evaluation after a full course of neoadjuvant treatment.
23. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22:900-908. The findings of this FDG-PET study pave the way for early response prediction and future response-based trials in (esophageal) cancer surgery. A decrease of the glucose metabolism of a tumor under neoadjuvant treatment could be demonstrated as early as 14 days after initiation of treatment and was a reliable marker for the response.
24. Heeren PA, Kloppenberg FW, Hollema H, et al. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 2004; 24:2579-2583.
25. Nakamura T, Hayashi K, Ota M, et al. Expression of p21 predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis Esophagus 2004; 17:315-321.
26. Sohda M, Ishikawa H, Masuda N, et al. Pretreatment evaluation of combined HIF-1 alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 2004; 110:838-844.
27. Miyazono F, Metzger R, Warnecke-Eberz U, et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 2004; 91:666-672.
28. Warnecke-Eberz U, Metzger R, Miyazono F, et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004; 10:3794-3799.
29. Siewert JR, von Rahden BHA, Stein HJ. Current Status of Esophageal Cancer - West versus East: The European Point of View. Esophagus 2004; 1:147-159.
30. Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234:360-367.
31. Mariette C, Finzi L, Piessen G, Van Seuningen I, Triboulet JP. Esophageal Carcinoma: Prognostic Differences between Squamous Cell Carcinoma And Adenocarcinoma. World J Surg. 2004. [Epub ahead of print, Dec 9]. The well-known and clinically important differences between squamous cell cancers and adenocarcinomas are increasingly acknowledged.
32. Brücher BL, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer 2001; 92:2228-2233.
33. von Rahden BH, Stein HJ, Feith M, et al. Lymphatic Vessel Invasion As a Prognostic Factor in Patients With Primary Resected Adenocarcinomas of the Esophagogastric Junction. J Clin Oncol 2005; 23:874-879. The prevalence of tumor cells in lymphatic vessels is a negative prognostic factor in adenocarcinomas of the esophagogastric junction and should be included as L category into the TNM staging system of the UICC.
34. Feith M, Stein HJ, Siewert JR. Pattern of lymphatic spread of Barrett's cancer. World J Surg 2003; 27:1052-1057.
35. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240:962-972. This retrospective analysis of a large surgical series indicates a rather unexpected high prevalence of cervical lymph node metastases, even in esophageal cancer of the distal esophagus.
36. Tabira Y, Okuma T, Sakaguchi T, et al. Three-field dissection or two-field dissection?-A proposal of new algorithm for lymphadenectomy. Hepatogastroenterology 2004; 51:1015-1020.
37. Cense HA, Visser MR, van Sandick JW, et al. Quality of life after colon interposition by necessity for esophageal cancer replacement. J Surg Oncol 2004; 88:32-38. Functional results as well as quality of life are poor with colon interposition used for reconstruction after esophagectomy.
38. Tabira Y, Sakaguchi T, Kuhara H, et al. The width of a gastric tube has no impact on outcome after esophagectomy. Am J Surg 2004; 187:417-421.
39. Schmidt CE, Bestmann B, Kuchler T, et al. Quality of life associated with surgery for esophageal cancer: differences between collar and intrathoracic anastomoses. World J Surg 2004; 28:355-360.
40. Siewert JR, Stein HJ, Bartels H. ([Anastomotic leaks in the upper gastrointestinal tract]) Chirurg 2004; 75:1063-1070.
41. Rizk NP, Bach PB, Schrag D, et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg 2004; 198:42-50. Surgical complications like anastomotic leaks, chylothoraces, etc., are affecting outcome parameters like mortality and survival.
42. Hünerbein M, Stroszczynski C, Moesta KT, Schlag PM. Treatment of thoracic anastomotic leaks after esophagectomy with self-expanding plastic stents. Ann Surg 2004; 240:801-807. This retrospective analysis demonstrates the feasibility and beneficial role of stent placement for management of intrathoracic anastomotic leakages.
43. Tomaselli F, Maier A, Sankin O, et al. Ultraflex stent-benefits and risks in ultimate palliation of advanced, malignant stenosis in the esophagus. Hepatogastroenterology 2004; 51:1021-1026.
44. Xinopoulos D, Dimitroulopoulos D, Moschandrea I, et al. Natural course of inoperable esophageal cancer treated with metallic expandable stents: quality of life and cost-effectiveness analysis. J Gastroenterol Hepatol 2004; 19:1397-1402.
45. Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364:1497-1504. This multicenter study compares two methods commonly used for palliation of dysphagia due to malignant esophageal stenosis from inoperable esophageal malignancies, and indicates a superiority of single-dose brachytherapy.
46. Homs MY, Essink-Bot ML, Borsboom GJ, et al. Dutch SIREC Study Group. Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer 2004; 40:1862-1871.